In addition, patients with heart failure due to ischemic heart disease who had NT-proBNP values <103 pmol/L (868 pg/mL) had the best prognosis and, if assigned to rosuvastatin rather than placebo, had a greater reduction in the primary endpoint (HR 0.65, 95% CI 0.47–0.88) than patients in the other tertiles (heterogeneity test, p = 0.0192). This evidence concerns the gene NPPB and coronary artery disorder.